Liver cancer is a leading cause of cancer deaths worldwide.1 Early detection facilitates a greater chance of survival.2 If detected early, the 5 year survival rate increases from 15% up to 70% with appropriate interventional treatment.3
The Challenge:
Surveillance programs facilitate earlier cancer detection, earlier access to curative treatments and greater patient survival.2 46% of enrolled patients in surveillance programs had significant increases in 5 year survival due to early tumor detection.4
How We Help:
Enhance Liver Cancer Surveillance using FUJIFILM’s AFP-L3 and DCP tests
Dr. Yang: Section 1
Dr. Yang: Section 2
Dr. Yang: Section 3
Dr. Yang: Section 4
Dr. Yang: Section 5
Dr. Yang: Section 6
Dr. Yang: Section 7
Dr. Yang: Section 8
Dr. Yang: Section 9
Dr. Yang: Section 10
Dr. Charlton: Case Base HCC Screening & Surveillance
Dr. Charlton: Case Base HCC Screening & Surveillance (5 mins)
Contact Us
Please contact us for further inquiries of FUJIFILM's liver biomarkers AFP-L3 and DCP and uTASWako i30 system.
